SB
Skye Bioscience is a biopharmaceutical company developing first-in-class monoclonal antibodies that inhibit the peripheral CB1 receptor to promote sustainable weight loss and improve metabolic health. Their lead candidate, nimacimab, aims to enhance drug tolerability and patient adherence with potential dosing intervals of once a week to once a month.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Skye Bioscience is a biopharmaceutical company developing first-in-class monoclonal antibodies that inhibit the peripheral CB1 receptor to promote sustainable weight loss and improve metabolic health. Their lead candidate, nimacimab, aims to enhance drug tolerability and patient adherence with potential dosing intervals of once a week to once a month.